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Abstract
Background: Early diagnosis and prompt, effective treatment of uncomplicated malaria is critical to prevent severe disease,
death and malaria transmission. We assessed the impact of rapid malaria diagnostic tests (RDTs) by community health
workers (CHWs) on provision of artemisinin-based combination therapy (ACT) and health outcome in fever patients.
Methodology/Principal Findings: Twenty-two CHWs from five villages in Kibaha District, a high-malaria transmission area in
Coast Region, Tanzania, were trained to manage uncomplicated malaria using RDT aided diagnosis or clinical diagnosis (CD)
only. Each CHW was randomly assigned to use either RDT or CD the first week and thereafter alternating weekly. Primary
outcome was provision of ACT and main secondary outcomes were referral rates and health status by days 3 and 7. The
CHWs enrolled 2930 fever patients during five months of whom 1988 (67.8%) presented within 24 hours of fever onset. ACT
was provided to 775 of 1457 (53.2%) patients during RDT weeks and to 1422 of 1473 (96.5%) patients during CD weeks
(Odds Ratio (OR) 0.039, 95% CI 0.029–0.053). The CHWs adhered to the RDT results in 1411 of 1457 (96.8%, 95% CI 95.8–97.6)
patients. More patients were referred on inclusion day during RDT weeks (10.0%) compared to CD weeks (1.6%). Referral
during days 1–7 and perceived non-recovery on days 3 and 7 were also more common after RDT aided diagnosis. However,
no fatal or severe malaria occurred among 682 patients in the RDT group who were not treated with ACT, supporting the
safety of withholding ACT to RDT negative patients.
Conclusions/Significance: RDTs in the hands of CHWs may safely improve early and well-targeted ACT treatment in malaria
patients at community level in Africa.
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Introduction
Malaria remains a leading cause of death among children in
sub-Saharan Africa [1] despite reports of reduced burden of
disease following wide scale deployment of modern control
interventions [2]. Since early diagnosis and prompt effective
treatment is essential to prevent fatal malaria, strategies to improve
access to treatment at community level have been endorsed by
WHO [3,4]. Early effective antimalarial treatment may also
reduce the risk of further transmission. Home-based management
of malaria (HMM), where members of the community treat
malaria patients, is therefore now being introduced in Africa.
Artemisinin-based combination therapy (ACT) is now generally
recommended as first-line treatment for uncomplicated malaria
globally [4]. In Africa, ACTs were recently found to be successfully
integrated in HMM strategies by community health workers
(CHWs) [5,6]. Malaria diagnosis is still, however, often based on
clinical symptoms in many parts of Africa resulting in over-
diagnosis and over-treatment. In mainland Tanzania, presumptive
malaria treatment is used in febrile children residing in malaria
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endemic areas, in accordance with the Integrated Management of
Childhood Illness (IMCI) strategy, as well as in older patients in
health facilities lacking confirmatory diagnostic facilities [7].
Presumptive malaria treatment with ACT is costly, may spur
development of drug resistance [8,9] and prevents other causes of
fever from being considered, diagnosed and appropriately treated.
A key challenge for improved case management of fever patients
in Africa is thus to provide early access to ACT at peripheral and
even community level after parasitological confirmation.
RDTs are antigen-based dipstick tests requiring neither a skilled
technician nor electricity, which makes them useful even in rural
areas [10,11]. Previous studies have confirmed their high
sensitivity and specificity under field conditions [12–16]. However,
health systems performance remains critical [17] and poor
adherence to test results with up to 50% of RDT negative
patients treated with ACT in effectiveness studies at health facility
level have raised concerns of the usefulness of RDTs [18–21].
Conversely, recent studies have reported higher adherence to
RDT negative results [22–23]. In addition to the adherence issue,
there is also debate as to the risk of withholding antimalarial
treatment especially in young children who test negative by RDT
for malaria [24–27].
Limited earlier studies suggest that RDTs can be accurately
used by CHWs [10,28] and recently, Yeboah-Antwi et al reported
promising results in Zambia where CHWs, previously trained in
curative care, were using RDTs, ACT and antibiotics for
management of children with fever [29]. In Tanzania CHWs
are normally not trained in curative care.
We studied the impact of RDT-aided management of fever
patients as compared with clinical diagnosis (CD) only by CHWs
on provision of ACT for uncomplicated malaria at community
level.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics
This study was approved by the Muhimbili University of Health
and Allied Sciences (ref MU/RP/AEC/Vol.IV/52) and by the
Regional Ethics Committee, Stockholm (2006/2:2). The patients
and/or their caretakers signed a written consent form at inclusion,
or provided a thumb print after the consent form was read to
them.
Study area and health care
The study was conducted during the peak malaria transmission
period (March–August 2006) in Kibaha District, a high-transmis-
sion area of Coast Region, Tanzania [30]. Eight villages were
initially selected for logistic reasons and for being catered by a
common second level health centre (Mlandizi). Five of these eight
villages, with a total population of 8625 people, were then selected
based on their rural location and limited availability of private
health care outside the existing public services.
Each of the five study villages had one village dispensary,
representing the first level of public health care. The five dispen-
saries were open daytime on weekdays and had 2–5 staff members,
including one clinical officer, one nurse, and usually a midwife.
Sunlight microscopy for malaria diagnosis was available in two of
the five dispensaries. By the time of the trial, there was no private
health facility, pharmacy or drug vendor in any of the selected
villages or within a distance of 10 km. The second level of health
care and thus referral facility for the dispensaries in the study area
was Mlandizi Health Centre, situated at a distance of 9 to 18 kms
from the selected villages. This 24-hour open health centre
provided basic laboratory services including malaria microscopy,
haemoglobin determination and urine and stool examination as
well as inpatient care, but no facilities for surgery, blood
transfusions or care for severely ill patients.
Community health workers
CHWs are an integrated part of the existing health care
infrastructure in Tanzania. They are appointed by the community
among the village members, but to be eligible, they must have
primary education. CHWs are trained in health promotion. In
recent years some have received additional training in demo-
graphic and health surveillance. However, CHWs do not receive
any formal education in health care. Hence, the CHWs had not
been involved in any routine curative services prior to the study.
After consultations with village leaders, district authorities and
dispensary staff, 22 active CHWs in the five selected villages were
asked to participate in the study. All provided informed consent.
The study CHWs included 12 men and 10 women, with age
ranging from 20 to 50 years. The CHWs were 2–6 per village
depending on population size, each CHW being responsible for
approximately 300 to 500 people. During the study period each
CHW was given a monthly allowance equivalent to 15 USD. The
CHWs were mostly farmers working in the vicinity of their homes.
They were to be available for any fever patient consultation most
of the day and at night.
Before the study, the CHWs received one week specific training
on malaria symptoms, performance and interpretation of RDT,
prescription of ACT (artemether-lumefantrine), identification of
danger signs according to IMCI and indications for referral. The
study specific training also included study design, blood sampling
and data handling. Instruction booklets for questionnaires and
other study procedures were provided to the CHWs. The primary
referral level during weekday working hours was the village
dispensary or else the Mlandizi Health Centre.
Community sensitization meetings were held prior to the study
start when the villagers were informed about the purpose and
conduct of the study.
Study design and outcomes
The intervention consisted of training CHWs in fever case
management using CD only or RDT aided diagnosis, and
provision of ACT for use in patients diagnosed with malaria. A
systematic random sampling data design was implemented. Each
of the 22 CHWs was assigned a unique number which was noted
on a lottery ticket. Eleven tickets were then picked blindly by one
researcher (AJ) from a box after mixing. The selected eleven
CHWs were allocated to start using RDT the first study week and
thereafter alternating with CD weekly. The remaining eleven
CHWs were allocated to use CD the first week. This cross over
design at CHW level was applied to account for seasonal and
geographic differences in malaria transmission and variations in
CHWs’ individual performance.
The primary outcome measure was proportion of patients
provided ACT during RDT and CD weeks. Secondary outcomes
included proportion of patients presenting within 24 hours of fever
onset, referral rates up to day 7, health outcome by day 3 and 7,
compliance to treatment and mortality up to day 28.
Patient inclusion, diagnosis and treatment
The sample unit was a patient with reported fever. The
inclusion criteria were history of fever in the preceding 24 hours in
Malaria Rapid Tests and ACT at Community Level
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patients above 3 months of age and informed consent from the
patient and/or parent/guardian. Exclusion criteria were pregnan-
cy, symptoms suggestive of severe disease and prior study inclusion
within the previous 28 days.
CHWs were to provide ACT based either on symptoms
suggestive of uncomplicated malaria during CD weeks and symp-
toms together with an RDT positive result during RDT weeks.
Thick blood smears were collected through finger pricks from all
enrolled patients. All blood smears were sent to a field research
laboratory established at Mlandizi Health Centre for Giemsa
staining and microscopical investigation. The microscopy results
were thus not available to guide treatment. Artemether-lumefan-
trine (CoartemH, Novartis, Basel, Switzerland) was to be
administered according to body weight/age groups in six doses
over three days as recommended by the manufacturer. Pre-
packaged doses with written information and illustrations for four
different weight/age groups were provided to the CHWs to ease
drug dispensing. The first dose of ACT was to be given under
CHW supervision. The patients/guardians were recommended to
preferably administer the remaining drug doses together with fatty
food. Paracetamol was provided to all fever patients. CHWs were
instructed to refer patients that they considered in need of other or
additional treatment to the village dispensary or if necessary, to
Mlandizi Health Centre.
Data collection and follow-up
Study questionnaires for data collection had been developed,
translated into Swahili and piloted and revised during the training of
CHWs. Field supervision for technical support, refill of supplies, and
collection of forms and blood smears of the CHWs were done
regularly throughout the study. Patients were asked to return to the
CHW routinely on days 3 and 7 and any day if they did not improve
or if symptoms deteriorated and finally also if they got fever again
within 28 days after enrolment. The CHW collected information on
patient’s subjective general health using four categories (‘‘fully
recovered’’, ‘‘better but still sick’’, ‘‘same’’, ‘‘worse’’) and also
possible side effects of ACT and intake of any additional treatment,
e.g. antibiotics. The CHW also collected a blood smear at the
routine check up day 7 and anytime a patient returned with fever.
For the day 3 follow-up, the patients were asked to bring the ACT
blister package to assess treatment compliance. Patients who did not
return for the scheduled day 7 visit were actively followed-up at
home by the CHW to collect health status information from the
patient, guardian, relative or neighbour.
RDT and microscopic examination
RDTs were used according to manufacturer’s instructions
(Paracheck Pf, Orchid Biomedical Systems, Goa, India). CHWs
were asked to save the positive RDTs for cross checking of the
result by the study team within a week from test performance.
Thick blood smears collected by the CHWs were sent to Mlan-
dizi where one study laboratory assistant performed Giemsa-
staining and microscopic examination in light microscopy (Olym-
pus) with oil immersion objective (magnification61000). Asexual
parasites were counted against 200 white blood cells and parasite
densities calculated assuming a white blood cell count of 8000/ml
blood. A blood smear was defined as negative if no parasites were
detected after ten minutes’ reading. Quality control was performed
by two experienced technicians blinded to the initial results at the
Department of Parasitology, Muhimbili University of Health and
Allied Sciences (2nd reader) and for 10% of the blood smears at the
Malaria Research Unit, Karolinska Institutet (3rd reader). The
result from the second reading was decisive whenever discordant
with field laboratory result.
Statistics and data analysis
Sample size calculation was done for independent data aiming
at 80% power and 5% significance level using Stata 10.0
(StataCorp LP, US). To detect a reduction in ACT prescriptions
with RDT aided diagnosis from 80% to 70%, each age group
(below 5 years of age, 5–14 years and 15 years and above) should
contain at least 314 patients. Given the study design, clustering at
CHW level (22 CHWs) was taken into account. For a sample of
480 patients per age group, the maximum intra-cluster coefficient
(ICC) values could be 0.025, still reaching 80% power [30]. The
planned study period was 16 weeks but patient recruitment was
slower than expected and enrolment was therefore extended to 20
weeks targeting 360 children below 5 years of age, 360 aged 5–14
years and 720 aged 15 years and above for RDT and CD weeks,
respectively, with an estimated 1:1:2 attendance ratio. A sample of
360 patients per age group would reach a power of 80% for ICC
values up to almost 0.01.
Data were entered in EpiData 3.1 (http://www.epidata.dk),
cleaned and analysed using EpiInfo 6.04d (CDC/WHO) and
Stata 10.0 (StataCorp LP, USAll frequencies, proportions and
odds ratios (ORs) presented were calculated with 95% confidence
intervals (CIs) and corresponding p-values. The ORs and their
standard errors were adjusted for clustering on CHW level using
mixed effect model. For the main outcome variables data are
presented for the three age groups. Significances are stated at the
5% level.
Results
During the 5-month study period 3005 patients with fever, of
whom 75 were excluded, consulted the 22 CHWs (Figure 1). The
remaining 2930 patients, including 760 children below 5 five years
of age, were thus included in the analysis. Some 153 and 7
individuals were enrolled twice and three times, respectively, with
fever episodes occurring more than 28 days apart. Each CHW
enrolled a mean of 133 patients (range 60–265). One CHW was
withdrawn from the study after 18 weeks due to absenteeism.
There was a balanced enrolment during the two different
intervention weeks, 1457 (49.7%) patients during RDT and 1473
(50.3%) during CD weeks. The enrolment was also found to be
balanced in terms of sex, age groups and duration of fever which
indicates that health seeking behaviour among patients was not
affected by the respective diagnostic intervention. Patient baseline
characteristics are presented in Table 1. A total of 1988 (67.8%)
patients including 486 (63.9%) children below 5 years of age
presented within 24 hours after onset of fever. Some 218 (7.4%)
patients presented at night.
During RDT weeks, 733 of 1457 (50.3%) patients were RDT
positive (Table 2), whereas 1416 of 1473 (96.1%) were clinically
classified as malaria during CD weeks. 732 out of 733 RDTs
interpreted as positive by CHWs were cross-checked by the
research team and only 2 (0.3%) had no activity band. The
microscopical reading in Mlandizi (first reader) detected parasites
in 643 of 2841 (22.6%) blood slides. The blood slide positivity rates
in the three age groups were 37.8%, 28.0% and 12.0%, respec-
tively. The sensitivity and specificity of RDTs compared to
microscopy results were 85.3% and 59.8%, respectively. Staining
quality was partly poor with auto-fixation of the thick films. The
field and central laboratory level microscopy results agreement
was 85% (kappa coefficient = 0.59). The sensitivity and specificity
of the initial field blood slide reading versus central laboratory
result was 69% and 90%, respectively.
ACT was provided to 775 of 1457 (53.2%) patients during RDT
weeks and to 1422 of 1473 (96.5%) patients during CD weeks (OR
Malaria Rapid Tests and ACT at Community Level
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0.039, 95% CI 0.029–0.053) (Table 2). The overall relative
reduction in provision of ACT during RDT weeks was thus
44.9%, and most prominent in patients 15 years and above
(57.3%). ACT was provided to 44 of 724 (6.1%) patients with
RDT negative results, whereas two patients were not treated
despite being RDT positive. Overall CHW adherence to RDT
results was thus recorded in 1411 of 1457 (96.8%, 95% CI 95.8–
97.6) patients. During CD weeks, 6 of 57 (10.5%) patients received
ACT despite being clinically classified as non-malaria.
Referral occurred more often in the RDT group compared to
the CD group (Table 3). Combining day 0 and day 1 to 7, 250 of
1457 (17.2%) patients were referred in the RDT group compared
to 73 of 1473 (5.0%) in the CD group (OR 4.3, 95% CI 3.2–5.7).
Among the 146 patients referred on day 0 in the RDT group, only
12 (8.2%) received ACT before referral. Similarly, in the CD
group, referral on day 0 was relatively more common among
patients who did not receive ACT. Main reasons for referral (80%)
were ‘‘fever but not malaria’’ (RDT negative), abdominal pain/
diarrhoea/vomiting, cough/chest pain and difficult breathing.
Other reasons included ear/eye problems, skin diseases, worms,
body pains, tonsillitis and flue.
Four patients died during the trial. Three children below 5 years
of age died within three days and one adult within seven days after
enrolment. Malaria diagnosis was confirmed by microscopy in two
deceased children (32,800 and 54,000 parasites/ml, respectively).
Both had initially been diagnosed with malaria (after RDT and
CD, respectively), prescribed ACT by the CHW and referred for
further management. The third child was both RDT and blood
smear negative and was not treated with ACT, but referred
directly to the dispensary due to breathing problems. Similarly, the
deceased adult was also RDT and blood smear negative, and
referred for management of stomach pain on day of enrolment.
Figure 1. Flow of patients through the study.
doi:10.1371/journal.pone.0019753.g001
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She reattended on day 3 with unchanged condition and was again
referred to the dispensary by the CHW. Apart from the two
deceased children with confirmed malaria infection no other
patients developed severe malaria.
Health outcome by day 3 and 7 in the RDT and CD group is
presented in Table 4. Information about health outcome by day 7
was obtained from 2869 of 2930 (97.9%) patients. The remaining
61 patients had left the study area at the time of follow-up and
were thus lost to follow-up.
Full recovery was more commonly reported in the CD group
(97.3%) compared to the RDT group (93.3%). Among the non-
recovered patients in the RDT group, 32 (27 RDT negative on
day 0) reported unchanged or worse condition on day 3, and 10 on
day 7. The corresponding numbers in the CD group were 8 and 4,
respectively. Among the 14 patients with unchanged or worse
condition on day 7, only one (CD group) had a positive blood slide
on day 7 (5,400 parasites/ml). Among 120 patients reporting
improvement but not complete recovery on day 7, three were
positive by microscopy, one (30,320 parasites/ml) in the RDT
group and two (35,600 and 45,200 parasites/ml) in the CD group.
Two of the four parasite positive patients on day 7 had been
prescribed ACT on day 0.
ACT treated patients more often reported full recovery than
ACT untreated, i.e. 97.3% versus 89.1% (OR 4.4, 95% CI 3.1–
6.3). However, the only two non-ACT treated patients despite
positive RDT result reported full clinical recovery by day 7 and
severe malaria did not develop in any of the overall 682 patients in
the RDT group who were not treated with ACT.
Withholding ACT in children with fever represents a special
concern. Among the 153 children below 5 years of age in the RDT
group, who were not treated with ACT, 26 were referred on day 0
and 3 upon reattendance on days 1–7. All blood slides (n = 40)
collected on day 7 routine follow-up were negative by microscopy.
This included blood slides from the 3 children who reported they
were not fully recovered.
During the 8–28 day passive follow-up a total of 16 patients (5
RDT and 11 CD), reattended the CHWs due to fever, of whom
seven were below 5 years of age and three had positive microscopy
(3,000, 5,840 and 123,520 parasites/ml) between day 23 and 28.
All three were from CD group and had received ACT at
enrolment.
Full ACT compliance, i.e. intake of whole regimen according to
dose schedule was reported by 2123 of 2156 (98.5%) ACT treated
patients who returned for day 3 follow-up. Reported compliance
was higher during CD-weeks (99.3%) than during RDT-weeks
(97.4%), (OR 3.3, 95% CI 1.5–7.7). Altogether 2115 patients
(96.3%) returned their ACT blister packages and 99.2% of these
were empty.
Adverse events interpreted as drug related were reported by 24
patients (1.1%). No drug related severe adverse event was
reported. The most common complaints were nausea, weakness,
headache and diarrhoea. Incomplete compliance to whole ACT
regimen was reported by 10 of these 24 patients compared to only
20 of 2131 patients not reporting adverse event (OR 143, 95% CI
43–500).
Discussion
This study demonstrates that the use of RDTs by CHWs can be
safe and effective for targeting ACTs to patients with uncompli-
cated malaria in sub-Saharan Africa [29]. RDT use significantly
reduced prescription of ACT by 45% as compared with CD, with
the most striking reduction of treatment for patients above 15
years (57%). Although appropriate use of ACT is especially
important in children, reduced over-use of ACT among adults will
be more drug-cost saving besides preventing unnecessary drug
exposure. The cross-over design of the study may potentially
influence attendance to either CD-week (higher chance for ACT)
or RDT-week (benefit of the RDT). However, neither preference
was observed since very similar attendances were found in CD-
and RDT-weeks, respectively (Table 1).
Table 1. Baseline characteristics of patients enrolled during
Rapid Diagnostic Test (RDT) and Clinical Diagnosis weeks.
Characteristics
RDT
N (%)
Clinical
Diagnosis
N (%)
Total number 1457 1473
Females 773 (53.1) 796 (54.0)
Age groups (years)
,5 368 (25.3) 392 (26.6)
5–14 380 (26.1) 365 (24.8)
$15 709 (48.6) 716 (44.6)
Duration of fever (hours)
,24 981 (67.3) 1007 (68.4)
24–48 347 (23.8) 332 (22.5)
.48 129 (8.9) 134 (9.1)
doi:10.1371/journal.pone.0019753.t001
Table 2. Proportions of patients prescribed artemisinin-based combination therapy (ACT) in Rapid Diagnostic Test (RDT) and
Clinical Diagnosis arms by age group.
RDT Clinical Diagnosis (1)
Age group
(years) Total RDT positive ACT treated Total ACT treated
n % (95% CI) n % (95% CI) n % (95% CI)
,5 368 205 55.7 (47.1–64.3) 215 58.4 (49.6–67.2) 392 381 97.2 (94.9–99.5)
5–14 380 258 67.9 (60.4–75.3) 268 70.5 (64.1–76.9) 365 350 95.9 (91.5–100)
$15 709 270 38.1 (33.3–42.8) 292 41.2 (35.5–46.9) 716 691 96.5 (92.4–100)
All patients 1457 733 50.3 (45.7–54.9) 775 53.2 (47.7–58.6) 1473 1422 96.5 (93.5–99.5)
(1) A total of 1416 were classified as probable malaria but an additional 6 (total 1422) were ACT treated.
doi:10.1371/journal.pone.0019753.t002
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The reduced provision of ACT after RDT use was achieved
following high adherence to RDT negative results. This may be
related to the specific CHW training and pre-study sensitization of
the community. Previous findings of poor adherence to negative
results at health facility level have been attributed to poor quality
of test and fear of false negative results [10,19] even after a three-
day training [20]. However, with a relatively short training high
adherence can also be achieved at primary health care level
[22,23]. It may also be that CHWs are more likely to comply with
simple clinical guidelines than other health care workers and that
they are relatively well suitable to influence patient compliance to
treatment [29,31]. The reported patient compliance to the
treatment (.95%) suggests that the complex regimen of
artemether-lumefantrine (6 doses over 3 days), as compared to
the previous single dose treatment of sulphadoxine-pyrimethamine
(SP), did not discourage patients from completing the treatment.
However, the study design with active follow-up and collection of
blister packages may also have influenced compliance to the full-
dose regimen. High community acceptability of ACT when
prescribed at community level has been described in two previous
Table 3. Proportions of patients referred to dispensaries following Rapid Diagnostic Test (RDT) and Clinical Diagnosis.
RDT Clinical Diagnosis OR* (95% CI) P-value
Total Referred % (95% CI) Total Referred % (95% CI)
Referral Day 0
,5 years 368 41 11.1 (7.9–14.4) 392 14 3.6 (1.7–5.4) 3.85 (1.97–7.53) 0.000
5 –14 years 380 28 7.4 (4.7–10.0) 365 4 1.1 (0.0–2.2) 7.35 (2.50–21.61) 0.000
$15 years 709 77 10.9 (8.5–13.2) 716 6 0.8 (0.1–1.5) 33.53 (13.19–85.18) 0.000
Not treated 682 134 19.6 (16.6–22.6) 51 8 15.7 (5.6–25.8) 0.76 (0.29–1.98) 0.578
Treated 775 12 1.5 (0.6–2.4) 1422 16 1.1 (0.5–1.7) 1.51 (0.69–3.27) 0.297
All patients 1457 146 10.0 (8.4–11.6) 1473 24 1.6 (0.9–2.3) 9.16 (5.77–14.54) 0.000
Referral Day 1–7
,5 years 368 35 9.5 (6.5–12.5) 392 14 3.6 (1.7–5.4) 2.84 (1.47–5.46) 0.002
5–14 years 380 12 3.2 (1.3–4.9) 365 4 1.1 (0.0–2.2) 2.92 (0.90–9.44) 0.073
$15 years 709 57 8.0 (6.0–10.0) 716 31 4.3 (2.8–5.8) 1.53 (0.94–2.47) 0.082
Not treated 682 78 11.4 (9.0–13.8) 51 3 5.9 (0.6–12.4) 1.92 (0.52–7.11) 0.327
Treated 775 26 3.4 (2.0–4.6) 1422 46 3.2 (2.3–4.2) 0.92 (0.55–1.52) 0.747
All patients 1457 104 7.1 (5.8–8.5) 1473 49 3.3 (2.4–4.2) 1.95 (1.36–2.80) 0.000
*ORs are adjusted for clustering on CHW level, see Statistics and data analysis-section.
doi:10.1371/journal.pone.0019753.t003
Table 4. Reported health outcome by day 3 and 7, respectively, in patients enrolled during Rapid Diagnostic Test (RDT) and
Clinical Diagnosis weeks.
RDT Clinical Diagnosis OR* (95% CI) P–value
Total n % Total n %
Full recovery Day 3
,5 years 336 274 81.5 382 342 89.5 0.55 (0.34–0.87) 0.010
5–14 years 347 312 89.9 360 344 95.6 0.45 (0.23–0.89) 0.021
$15 years 652 529 81.1 701 638 91.0 0.50 (0.34–0.71) 0.000
Treated 760 687 90.4 1399 1295 92.6 1.03 (0.73–1.44) 0.872
Not treated 575 428 74.4 44 29 65.9 2.47 (1.09–5.58) 0.030
All patients 1335 1115 83.5 1443 1324 91.8 0.52 (0.40–0.67) 0.000
Full recovery Day 7
,5 years 360 342 95.0 386 372 96.4 0.75 (0.36–1.53) 0.431
5–14 years 370 361 97.6 364 362 99.5 0.22 (0.04–1.03) 0.055
$15 years 681 614 90.2 708 684 96.6 0.35 (0.15–0.57) 0.000
Treated 764 743 97.3 1408 1371 97.4 1.11 (0.65–1.88) 0.704
Not treated 647 574 88.7 50 47 94.0 0.53 (0.15–1.90) 0.333
All patients 1411 1317 93.3 1458 1418 97.3 0.45 (0.30–0.65) 0.000
*ORs are adjusted for clustering on CHW level, see Statistics and data analysis-section.
doi:10.1371/journal.pone.0019753.t004
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studies conducted in sub-Saharan Africa but they did not address
compliance [5,32].
The health impact of RDT and targeted ACT will depend on
the safety of withholding ACTs and the benefit of additional non-
malaria treatment to RDT negative patients. Interestingly, no fatal
or severe malaria was reported among the patients not treated
with ACT. The two malaria patients with fatal outcome had both
been prescribed ACT and most importantly all 4 patients with
fatal outcome had been identified by the CHWs as potentially
severely ill and consequently referred to the village dispensary.
Considering that our study was conducted in a rural setting, where
any news of severe disease and death is likely to reach the CHW
instantly, we assume that the risk of any death or severe malaria
manifestation other than the reported is limited.
The potential benefits from increased attention to non-malarial
illnesses in RDT negative patients could not be documented in our
study. However, based on the RDT results, at least 50% of
patients during the CD weeks did not have malaria as cause of
fever and were potentially therefore incorrectly treated with ACT
only. Approximately 20% of RDT-negative patients were referred
compared to about 2% among RDT positive patients or patients
from the CD group. This suggests that the CHWs were well aware
that negative RDT results could indicate presence of diseases other
than malaria, which may need non-malarial treatment. Despite
this, the self-reported full recovery rate by day 7 was higher during
CD than RDT weeks. This may partly reflect satisfaction of having
been ACT treated, but it may also reflect remaining symptoms in
non-treated patients with low density parasitemia undetected by
RDT. The high recovery rate in the CD group also suggests that
most non-malaria fevers represent self limiting diseases, which do
not require other treatment such as antibiotics.
In our study, over 60% of the patients presented at the CHWs
within 24 hours of fever onset. In a recent report from Kenya only
23% of febrile children received ACT at health facility level within
48 hours [33], which is far from the target of treating 80% of
malaria episodes within the first 24 hours by 2010 [34]. In the
recent Tanzania Demographic and Health Survey 2010 based on
a national sample of 10300 households, 21% of children under five
were reported to have had fever in the two weeks preceding the
survey. Of these, 58% were given any anti-malarial treatment, but
just 28% took ACT within 48 hours [35].
Our results indicate that the CHW may represent an important
provider of early fever case management and thus access to ACT
in rural settings in Africa where many people live at considerable
distance from health care facilities [29,36]. In two previous studies
improved child survival has generally been observed when curative
services at community level have been provided by nurses [37],
but not by community volunteers [38]. A few smaller studies on
community or home-based management of malaria have shown
varying results on health outcomes [39].
The overall RDT positivity rate observed was higher than the
blood slide positivity rate. This may reflect false positivity (low
specificity) or higher sensitivity with RDT. False positive results
with HRP2 based RDTs, such as the one used in our trial, may
be due to persistent antigenemia in individuals recently treated
for malaria [40–42] and low specificities with HRP2 based RDTs
(about 70%) compared to microscopy have also been document-
ed in previous studies when used in primary health care settings
[41,43,44]. However, the higher positivity rate of RDTs retrieved
in our study compared to microscopy is probably also influenced
by the partly poor quality of blood slides. The validity of
microscopy in peripheral health facilities has previously been
questioned because of technical problems [45] and RDT results
may thus turn out to be more accurate than microscopy,
especially when the blood tests are performed at community level
by CHWs.
Conclusion
The role of CHWs in providing curative care is a matter of
debate. This study suggests that malaria RDTs in the hands of
CHWs provide an opportunity to improve access to early, well
targeted ACT treatment at community level as well as better
opportunity for non-malaria treatment, such as antibiotics for
pneumonia, at referral level. This is expected to reduce severe
disease and death in malaria and other diseases and also to reduce
the risk of development of ACT resistance. However, the effect
and impact of RDT including its cost effectiveness [15,46] will
depend on the local malaria endemicity and the accuracy of the
selected type of RDT in that local context. More studies are now
also required to improve management of non-malaria ( = RDT
negative) febrile patients including an optimal integration of
CHWs into the formal health care system.
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